Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

NCT05114837 | Withdrawn Phase 1 DMC FDA Drug

• 2 other identifiers: 2021LS012MT2021-02
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, single-arm, interventional phase I/II trial to evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg) in adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL). The study consists of two components. The dose finding component is a modified version of a Phase I trial and the extended component is a modified Phase II trial.

Conditions

Lymphoma Leukemia

Keywords

CAR19-tTreg

Outcome Measures

Primary Outcomes (2)

• Dose Finding of CAR19-tTregs

  To identify the MTD of CAR19-tTregs defined asthe dose level that most closely corresponds to a dose limiting toxicity rate(DLT) less than or equal to 25%. Using grade 3-5 Common Terminology Criteria for Adverse Events version 5 (CTCAEv5) Statistical Analysis: The proportion of patients with ORR, CR and adverse events by day 28 will be estimated by simple proportions with 95% confidence intervals

  28 days after CAR19-tTregs administrations

• Measure CAR19-tTregs efficacy

  Efficacy estimate as measured by overall response rate

  28 days after CAR19-tTregs administrations

Secondary Outcomes (7)

• Incidence of CR

  28 days after CAR19-tTregs administrations

• Incidence of grade 3-4 cytokine release syndrome (CRS)

  28 days after CAR19-tTregs administrations

• Incidence of immune cell associated neurotoxicity syndrome (ICANS)

  28 days after CAR19-tTregs administrations

• Incidence of relapse in patients achieving complete response (CR)

  1 year after treatment

• Incidence of relapse in patients achieving complete (CR)

  Day +100 after treatment

Study Arms (1)

Phase I/II

EXPERIMENTAL

Determine the maximum tolerated dose (MTD) of CAR19-tTreg. It will be administered in a single dose after high dose lymphodepleting chemotherapy to promote adoptive transfer. First dose of 1.0 x 10 6 CAR19-tTreg/kg recipient body weight (dose level 1).The subsequent doses are 3.0, 10.0 and 30.0 x 10 6 CAR19- tTreg/kg. PHASE II Expand trial on maximum tolerated dose (MTD) of CAR19-tTreg from Phase I. It will be administered in a single dose after high dose lymphodepleting chemotherapy to promote adoptive transfer.The CAR19-tTreg/kg dose is to be determined.

Drug: allogeneic CAR19 regulatory T cells (CAR19-tTreg); Drug: Fludarabine; Drug: Cyclophosphamide

Interventions

allogeneic CAR19 regulatory T cells (CAR19-tTreg) DRUG

A single dose administration of CAR19-tTreg

Phase I/II

Fludarabine DRUG

Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)

Also known as: FLUDARA

Phase I/II

Cyclophosphamide DRUG

Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)

Also known as: CYTOXAN

Phase I/II

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of R/R CD19+ B-ALL after failure of standard of care therapies with CD19 expression on blasts confirmed by flow cytometry or immunohistochemistry and meeting one or more of the following criteria:
• Primary induction failure with no complete remission after ≥2 cycles of induction chemotherapy/immunotherapy, or
• First relapse with no CR after 1 cycle of induction therapy, or
• Second or greater relapse, or
• Ph+ ALL and failure or intolerance to three lines of tyrosine kinase inhibitors (TKI) assuming one or more of the above criteria are also met.
• Karnofsky performance status (KPS) ≥70% at screening
• Adequate organ function is defined as:
• Renal: Calculated estimated glomerular filtration rate greater than or equal to50 mL/min/1.73 m2
• Hepatic: ALT and AST less than 3x upper limit of normal (ULN), and bilirubin less than2x ULN (exception, patients with Gilbert syndrome, total less than 3 x ULN and direct less than 1.5 x ULN)
• Cardiac: Left ventricular ejection fraction (LVEF) greater than 45% by echocardiogram
• Pulmonary: SpO2 greater than 92% on room air
• Use of antiproliferative chemotherapy more than 2 weeks prior to enrollment and blinatumomab more than 4 weeks prior to enrollment
• Patients with relapsed disease after prior allogeneic transplantation may be considered. In addition to the eligibility criteria otherwise listed, this subgroup must be more than 3 months from allogeneic hematopoietic stem cell transplant (HSCT), off immune suppressive therapy (e.g., calcineurin inhibitor, glucocorticoid, sirolimus) at least 4 weeks without GVHD.
• Patients who received prior CAR-T therapy are eligible if more than 2 months after CAR-T infusion and CD19 expression is confirmed at the most recent relapse and all other criteria are met
• Voluntary informed consent by the patient for treatment and follow-up for 15 years after treatment.

You may not qualify if:

• Availability of a FDA approved CAR T cell therapeutic targeting CD19+ B-ALL (patients eligible for but unable to receive FDA approved CAR T cells based on insurance limitations, may be eligible for the proposed trial)
• Use of pharmacological immunosuppressive agents within 2 weeks (with the exception of physiologic or stress dose glucocorticoid replacement) or anti-T cell antibodies within 2 months of study participation
• Diagnosis of Burkitt lymphoma
• Diagnosis of active central nervous system (CNS) leukemia
• Known allergy to manufacturing components: human albumin or dimethylsulfoxide (DMSO)
• History of HIV infection on anti-retroviral therapy
• Positive for hepatitis B or hepatitis C
• Active uncontrolled bacterial, fungal, or viral infections - all prior infections must have resolved or be improving following optimal therapy
• Active autoimmune disease requiring immunosuppressive therapy
• Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, or supraventricular tachyarrhythmia requiring chronic therapy)
• Females who are pregnant or breastfeeding
• Unstable angina, arrhythmias, evidence of acute ischemia or conduction system abnormalities by electrocardiogram (ECG) or myocardial infarction in prior to 2 months
• Use of other investigational agents within 2 weeks

Sponsors & Collaborators

• Masonic Cancer Center, University of Minnesota: lead

Study Sites (1)

Masonic Cancer Center - University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location

MeSH Terms

Interventions

fludarabine; fludarabine phosphate; Cyclophosphamide

Intervention Hierarchy (Ancestors)

Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Hydrocarbons; Organic Chemicals; Phosphoramides; Organophosphorus Compounds

Study Officials

• Bachanova Veronika, MD

  Masonic Cancer Center, Univeristy of Minnesota

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg)

Study Record Dates

• First Submitted: October 29, 2021
• First Posted: November 10, 2021
• Study Start: September 1, 2024
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): August 1, 2028
• Last Updated: July 19, 2024

Record last verified: 2024-07

Locations

US (1)